The EuBIVAS Project: Within- and Between-Subject Biological Variation Data for Serum Creatinine Using Enzymatic and Alkaline Picrate Methods and Implications for Monitoring

dc.contributor.authorCarobene, Anna
dc.contributor.authorMarino, Irene
dc.contributor.authorCoskun, Abdurrahman
dc.contributor.authorSerteser, Mustafa
dc.contributor.authorUnsal, Ibrahim
dc.contributor.authorGuerra, Elena
dc.contributor.authorBartlett, William A.
dc.contributor.authorSandberg, Sverre
dc.contributor.authorAarsand, Aasne Karine
dc.contributor.authorSylte, Marit Sverresdotter
dc.contributor.authorRoraas, Thomas
dc.contributor.authorSolvik, Una Orvim
dc.contributor.authorFernandez-Calle, Pilar
dc.contributor.authorDiaz-Garzon, Jorge
dc.contributor.authorTosato, Francesca
dc.contributor.authorPlebani, Mario
dc.contributor.authorJonker, Niels
dc.contributor.authorBarla, Gerhard
dc.contributor.authorCeriotti, Ferruccio
dc.contributor.authorVariation, E.F.L.M. Working Grp Biol
dc.date.accessioned2023-02-21T12:41:22Z
dc.date.available2023-02-21T12:41:22Z
dc.date.issued2017-01-01
dc.description.abstractBACKGROUND: The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) European Biological Variation Study (EuBIVAS) has been established to deliver rigorously determined biological variation (BV) indices. EuBIVAS determined BV for serum creatinine using the enzymatic and alkaline picrate measurement methods. METHOD: In total, 91 healthy individuals (38 males, 53 females
dc.description.abstractage range, 21-69 years) were bled for 10 consecutive weeks at 6 European laboratories. An equivalent protocol was followed at each center. Sera were stored at -80 degrees C before analysis. Analyses for each patient were performed in duplicate within a single run on an ADVIA 2400 system (San Raffaele Hospital, Milan). The data were subjected to outlier and homogeneity analysis before performing CV-ANOVA to determine BV and analytical variation (CVA) estimates with confidence intervals (CI). RESULTS: The within-subjectBVestimates {[}CVI (95\% CI)] were similar for enzymatic {[}4.4\% (4.2-4.7)] and alkaline picrate {[}4.7\% (4.4-4.9)] methods and lower than the estimate presently available online (CVI = 5.9\%). No significant male/female BV differences were found. Significant differences were observed in mean creatinine values between men and women and between Turkish individuals and those of other nationalities. Between-subject BV (CVG) estimates, stratified accordingly, produced CVG values similar to historical BV data. CVA was 1.1\% for the enzymatic and 4.4\% for alkaline picrate methods, indicating that alkaline picrate methods fail to fulfill analytical performance specifications for imprecision (CVAPS). CONCLUSIONS: The serum creatinine CVI obtained by EuBIVAS specifies a more stringent CVAPS than previously identified. The alkaline picrate method failed to meet this CVAPS, raising questions regarding its future use. (C) 2017 American Association for Clinical Chemistry
dc.description.issue9
dc.description.issueSEP
dc.description.pages1527-1536
dc.description.volume63
dc.identifier.doi10.1373/clinchem.2017.275115
dc.identifier.urihttps://hdl.handle.net/11443/2711
dc.identifier.urihttp://dx.doi.org/10.1373/clinchem.2017.275115
dc.identifier.wosWOS:000408421200016
dc.publisherAMER ASSOC CLINICAL CHEMISTRY
dc.relation.ispartofCLINICAL CHEMISTRY
dc.titleThe EuBIVAS Project: Within- and Between-Subject Biological Variation Data for Serum Creatinine Using Enzymatic and Alkaline Picrate Methods and Implications for Monitoring
dc.typeArticle

Files

Collections